Enovis Corporation (NYSE: ENOV), a leading innovator in medical technology, has announced the appointment of Damien McDonald as its new Chief Executive Officer, effective May 12, 2025. McDonald will also join the company’s Board of Directors following the conclusion of Enovis’s Annual Meeting of Stockholders on May 21, 2025.
McDonald brings over 35 years of experience in the medical device industry to Enovis. He most recently served as CEO of LivaNova, a global medical technology company specializing in cardiac surgery and neuromodulation. During his six-year tenure at LivaNova, McDonald was credited with enhancing growth, profitability, and shareholder value, while fostering a ‘Patients First’ culture within the organization.
Prior to his role at LivaNova, McDonald held several senior leadership positions in the medical technology sector. He was a Group Executive and Corporate Vice President at Danaher, overseeing a $1.5 billion portfolio of dental consumables companies. Additionally, he led Zimmer’s spine division and managed global marketing for Johnson & Johnson’s Ethicon business unit.
Enovis’s decision to appoint McDonald follows the planned retirement of current CEO Matt Trerotola, who announced his intention to step down earlier this year. Trerotola, who has led the company since its days as Colfax Corporation, will not seek re-election to the Board and will transition to an advisory role to ensure a smooth leadership change.
“Damien has the experience, track record, and cultural fit to be a fantastic next leader of Enovis,” Trerotola stated. “I am grateful for the opportunity to lead Colfax and Enovis for the past decade and look forward to a smooth transition that continues to build on the company’s great operational and strategic momentum.”
Sharon Wienbar, Lead Independent Director at Enovis, expressed confidence in McDonald’s appointment, noting his alignment with the company’s culture and strategic vision. “His strong track record as CEO of a public, global medical technology company, combined with his long history of relevant business successes and his similar approach to business processes and culture, make him the right leader for Enovis at this stage in our growth journey,” Wienbar said.
McDonald expressed enthusiasm about joining Enovis during a pivotal time in its evolution. “I am honored to join the Enovis team at this exciting time in the company’s history and to have the opportunity to lead the company into its next phase of growth,” he said. “I share the company’s vision of developing innovative technologies to improve patient outcomes and I look forward to building upon Enovis’s strong foundation and delivering exceptional value for all of our stakeholders.”
Enovis has been actively expanding its presence in the orthopedic reconstruction sector, notably through the acquisition of LimaCorporate for approximately $847 million. This strategic move has positioned Enovis as a significant player in the $4 billion to $5 billion orthopedic reconstruction market, with the company aiming to sustain above-market growth in this area.
In conjunction with the leadership transition, Enovis reaffirmed its financial guidance for the first quarter of 2025, projecting revenues between $555 million and $563 million and adjusted EBITDA ranging from $97 million to $100 million.
As Enovis embarks on this new chapter under McDonald’s leadership, the company remains committed to its mission of delivering clinically differentiated solutions that enhance patient outcomes and transform healthcare workflows.
